Ein Unternehmen der RHÖN-KLINIKUM AG
-->

Publikationen

  • Refinement of screening for familial pancreatic cancer.
    Bartsch DK, Slater EP, Carrato A, Ibrahim IS, Guillen-Ponce C, Vasen HF, Matthäi E, Earl J, Jendryschek FS, Figiel J, Steinkamp M, Ramaswamy A, Vázquez-Sequeiros E, Muñoz-Beltran M, Montans J, Mocci E, Bonsing BA, Wasser M, Klöppel G, Langer P, Fendrich V, Gress TM.
    Gut. 2016 Aug;65(8):1314~21. doi: 10.1136/gutjnl-2015- 311098. Epub 2016 May 24.

  • Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
    Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM2, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vázquez-Sequeiros E, Sanjuanbenito A, Munoz- Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK.
    J Clin Oncol. 2016 Jun 10;34(17):2010-2019. doi: 10.1200/JC0.2015.64.0730. Epub 2016 Apr 25.

  • Familial Pancreatic Cancer: To Screen or not to Screen.
    Vasen HF, Bartsch DK
    EBioMedicine 2:1858-1859 (2015)

  • Limited resection of pancreatic cancer in high-riskpatients can result in a secondprimary.
    Potjer TP, Bartsch DK, Slater EP, Matthäi E, Bonsing BA, Vasen HF.
    Gut 2015;64(8): 1342-4. doi: 10.1136/gutjnl-2015-309568. Epub 2015 Apr 2.

  • MicroRNAs 196a and 196b as potential biomarkers for the early detection of familial pancreatic cancer.
    Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Klöppel G, Matthäi E, Heeger K, Fendrich V, Langer P, Bartsch DK.
    Transl Oncol 2014;7(4):464-71.

  • LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer
    Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthäi E, Chaloupka B, Gress TM, Langer P, Bartsch DK.
    Transl Oncol 2013; 6:99-103.

  • Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?
    Bartsch DK, Dietzel K, Bargello M, Matthaei E, Klöppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, Langer P.
    Fam Cancer 2013; 12:89-96.

  • Variation in Precursor Lesions of Pancreatic Cancer among High-Risk Groups.
    Potjer TP, Schot I, Langer P, Heverhagen JT, Wasser MN, Slater EP, Klöppel G, Morreau HM, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bargello M, Gress TM, Vasen HF, Bartsch DK; on behalf of the Leiden Familial Pancreatic Cancer Group and the FaPaCa registry.
    Clin Cancer Res. 2013; 19:442-449.

  • Familial pancreatic cancer- current knowledge
    Bartsch DK, Gress TM, Langer P.
    Nat Rev Gastroenterol Hepatol 2012; 9:445-453.

  • Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
    Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I.
    J Pathol 2012; 226:723-734.

  • Inactivation of Brca2 cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer.
    Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.
    Cancer Biol Ther 2011; 11:959-968.

  • German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.
    Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, Bartsch DK.
    Fam Cancer 2011; 10(2):323-30 Epub 2011 Jan 5.

  • The Angiotensin-I-converting Enzyme Inhibitor Enalapril and Aspirin delay progression of Pancreatic Intraepithelial Neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
    Fendrich V, Chen NM, Neef M, Waldmann J, Bucholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK.
    Gut. 2010 May;59(5):630-7. Epub 2009 Nov 1.

  • PALB2 mutations in European familial pancreatic cancer families.
    Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos J, Greenhalf W, Bartsch DK. 2010.
    Clin Genet. 78(5):490-4 Epub 2010 Mar 18.

  • Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.
    Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E, Sina M, Hahn SA, Bartsch DK. 2010.
    Fam Cancer. 9(3):335-43 Epub 2010 Feb 27.

  • Clinical and genetic analysis of 18 Pancreatic Carcinoma/Melanoma-Prone Families.
    Bartsch DK, Langer P, Habbe N, Matthäi E, Chaloupka B, Sina M, Hahn SA, Slater EP. 2010.
    Clin Genet 77(4):333-341 Epub 2009 Dec 22.

  • Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.
    Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK.
    Gut. 2009 Oct;58(10): 1321-2.

  • 5 Years of Prospective Screening of High Risk Individuals from Familial Pancreatic Cancer - Families.
    Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK
    Gut. 2009 May 25.

  • Hereditäres Pankreaskazinom
    Habbe N, Langer P, Bartsch DK.
    Chirurg. 2008 Nov; 79(11):1029-37.

  • Palladin Mutation Causes Familial Pancreatic Cancer: Absence in European Families.
    Slater E, Amrillaeva V, Fendrich V, Bartsch D, Earl J, Vitone LJ, Neoptolemos JP, Greenhalf W.
    PLoS Med 2007; 4(4): e164.

  • Evaluation of the 4q32-34 locus in European familial pancreatic cancer.
    Earl J, Yan L, Vitone LJ, Risk J, Kemp SJ, McFaul C, Neoptolemos JP, Greenhalf W; European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer, Kress R, Sina-Frey M, Hahn SA, Rieder H, Bartsch DK; German National Case Collection for Familial Pancreatic Cancer.
    Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1948-55.

  • Low frequency of CHEK2 mutations in familial pancreatic cancer.
    Bartsch DK, Krysewski K, Sina-Frey M, Fendrich V, Rieder H, Langer P, Kress R, Schneider M, Hahn SA, Slater EP.
    Fam Cancer. 2006; 5(4):305-8.

  • Familial pancreatic cancer syndromes.
    Habbe N, Langer P, Sina-Frey M, Bartsch DK.
    Endocrinol Metab Clin North Am. 2006 Jun;35(2):417-30, xi. Review.

  • Prophylaktische Pankreaschirurgie
    Langer P, Rothmund M, Bartsch DK.
    Chirurg. 2006 Jan; 77(1):25-32. Review. German

  • Anticipation in familial pancreatic cancer.
    McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP, Kress R, Sina-Frey M, Rieder H, Hahn S, Bartsch DK; European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC); German National Case Collection for Familial Pancreatic Cancer (FaPaCa).
    Gut. 2006 Feb; 55(2):252-8. Epub 2005 Jun 21.

  • RNASEL germline variants are associated with pancreatic cancer.
    Bartsch DK, Fendrich V, Slater EP, Sina-Frey M, Rieder H, Greenhalf W, Chaloupka B, Hahn SA, Neoptolemos JP, Kress R.
    Int J Cancer. 2005 Dec 10; 117(5):718-22.

  • Genetics of hereditary pancreatic carcinoma.
    Hahn SA, Bartsch DK.
    Clin Lab Med. 2005 Mar; 25(1):117-33. Review.

  • Genetics of hereditary pancreatic carcinoma.
    Hahn SA, Bartsch DK.
    Gastroenterol Clin North Am. 2004 Dec; 33(4):919-34, ix. Review.

  • No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma.
    Grützmann R, McFaul C, Bartsch DK, Sina-Frey M, Rieder H, Koch R, McCarthy E, Greenhalf W, Neoptolemos JP, Saeger HD, Pilarsky C.
    Cancer Lett. 2004 Oct 8; 214(1):63-8.

  • Prevalence of familial pancreatic cancer in Germany.
    Bartsch DK, Kress R, Sina-Frey M, Grützmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Pridöhl O, Ghadimi MB, Horstmann O, von Bernstorff W, Jochimsen L, Schmidt J, Eisold S, Estévéz-Schwarz L, Hahn SA, Schulmann K, Böck W, Gress TM, Zügel N, Breitschaft K, Prenzel K, Messmann H, Endlicher E, Schneider M, Ziegler A, Schmiegel W, Schäfer H, Rothmund M, Rieder H.
    Int J Cancer. 2004 Jul 20; 110(6):902-6.

  • Familial pancreatic cancer.
    Rieder H, Bartsch DK.
    Fam Cancer. 2004; 3(1):69-74. Review.

  • NOD3020insC mutation and the risk of familial pancreatic cancer.
    Nej K, Bartsch DK, Sina-Frey M, Rieder H, Hahn SA, Lubinski J.
    The Hered Cancer Clin Pract 2: (2004)149-150.

  • BRCA2 germline mutations in familial pancreatic carcinoma.
    Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grützmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK.
    J Natl Cancer Inst. 2003 Feb 5; 95(3):214-21

  • Pancreatic cancer and basal-cell carcinoma.
    Sina-Frey M, Bartsch DK, Grundei T, Grützmann R, Rieder H.
    Lancet. 2003 Jan 11; 361(9352):180.

  • CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H.
    Ann Surg. 2002 Dec; 236(6):730-7.

  • German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families.
    Rieder H, Sina-Frey M, Ziegler A, Hahn SA, Przypadlo E, Kress R, Gerdes B, Colombo Benkmann M, Eberl T, Grützmann R, Lörken M, Schmidt J, Bartsch DK.
    Onkologie. 2002 Jun; 25(3):262-6.

  • Familial pancreatic cancer--concept for study of the National Case Collection and early diagnosis program for high risk people.
    Gerdes B, Kress R, Rieder H, Sina-Frey M, Przypadlo E, Barth P, Rehder H, Hahn SA, Schmiegel W, Rothmund M, Ziegler A, Bartsch DK.
    Z Arztl Fortbild Qualitatssich. 2002 May; 96(4):251-5.

  • Update of familial pancreatic cancer in Germany.
    Bartsch DK, Sina-Frey M, Ziegler A, Hahn SA, Przypadlo E, Kress R, Gerdes B, Rieder H.
    Pancreatology. 2001; 1(5):510-6.